We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00532519
First Posted: September 20, 2007
Last Update Posted: September 20, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hadassah Medical Organization
September 19, 2007
September 20, 2007
September 20, 2007
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis
Not Provided

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Prurigo Nodularis
Drug: citalopram (cipralex)
10-20 mg/day, for 12 weeks.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00532519
horcoop-hmo-ctil
Yes
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: liran horev, md Hadassah Medical Organization
Principal Investigator: rena cooper-kazaz, md Hadassah Medical Organization
Hadassah Medical Organization
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP